Products and Services
Nov. 7, 2018 - Gateway presented and won the BioSTL Award on the 10th Startup Connection Venture Showcase in St. Louis.
August 2018 - Received NIH SBIR phase I grant award on "Development of a new colon-targeting and rapid-release metronidazole treatment
for Clostridium difficile infection".
June 2018 - Better Tomorrow Dietary Supplement, developed by Gateway to our partner Better Tomorrow LLC, launched on the US market.
February 2018 - Gateway's Metronidazole Delayed-Release Capsules received a QIDP (Qualified Infectious Disease Product) designation from FDA for the treatment of Clostridium difficile infection, which qualifies this product for a fast review and a 5-year exclusivity extension.
January 2018 - Gateway filed US patent application 20180000740A1 entitled "Pharmaceutical Compositions for Colon-Specific Delivery".
March 2017 - Completed Pre-IND package of a 505 b2 product for Clostridium difficile Infection and received Written Response from FDA.
June 2016 - New colon drug delivery system patent is filed in China with China PTO.
March 2016 - A new 505(b) drug delivery system patent has been filed with US PTO. This drug delivery system is one of a kind with targeted delivery in the colon.
October 2016 - Invited Speaker at "6th Annual Drug Delivery and Formulation Asia Summit" at Shanghai, China.
July 2015 - New formulation development for a NDA drug focusing on improving drug efficacy, resulting in a strategic partnership with clinical practitioners.
2015 to present - Successfully performed technology transfer of ANDA formulations and their process to strategic partners.